Kooner J S, Birch R, Frankel H L, Peart W S, Mathias C J
Department of Medicine, St. Mary's Hospital, London, UK.
Circulation. 1991 Jul;84(1):75-83. doi: 10.1161/01.cir.84.1.75.
Clonidine, a partial presynaptic and postsynaptic alpha-adrenoceptor agonist, has been shown to lower blood pressure in normal subjects but not in tetraplegics; however, the mechanisms of this action have not been elucidated.
The hemodynamic and hormonal basis of the hypotensive action of clonidine was investigated in tetraplegics with complete cervical spinal cord transection and preganglionic sympathetic denervation, in patients with unilateral brachial plexus injury and postganglionic sympathetic denervation, and in normal subjects. In normal subjects, the fall in blood pressure after clonidine infusion was accompanied by a reduction in cardiac output that was predominantly due to a fall in stroke volume and in heart rate. The lack of fall in blood pressure, cardiac output, and stroke volume in tetraplegics indicates that these effects are exerted at a supraspinal level and require intact descending sympathetic pathways. After clonidine infusion, digital skin vasodilatation occurred in normal subjects, in the innervated but not the denervated limb of patients with unilateral brachial plexus injury, and in tetraplegics, indicating that this response is due to the central sympatholytic effect of clonidine. Plasma norepinephrine was much lower in tetraplegics compared with normal subjects, and after clonidine infusion, it fell substantially in normal subjects alone. Plasma renin activity did not change. Bladder stimulation in tetraplegics resulted in a rise in blood pressure and vasoconstriction in digital skin vessels. The inability of clonidine to significantly reduce or abolish the pressor and digital vasoconstrictor responses after bladder stimulation in tetraplegics indicates that clonidine does not exert a major effect on spinal preganglionic neurons or peripheral presynaptic alpha 2-adrenoceptors.
Therefore, clonidine is a suitable drug for use in analyzing the central supraspinal levels of control in varying circulatory disorders, such as hypertension and postural hypotension.
可乐定是一种部分作用于突触前和突触后的α-肾上腺素能受体激动剂,已证实在正常受试者中可降低血压,但在四肢瘫痪者中则不然;然而,这种作用的机制尚未阐明。
在颈脊髓完全横断和节前交感神经去神经支配的四肢瘫痪者、单侧臂丛神经损伤和节后交感神经去神经支配的患者以及正常受试者中,研究了可乐定降压作用的血液动力学和激素基础。在正常受试者中,输注可乐定后血压下降伴随着心输出量减少,这主要是由于每搏输出量和心率下降所致。四肢瘫痪者血压、心输出量和每搏输出量未下降,表明这些作用是在脊髓以上水平发挥的,需要完整的下行交感神经通路。输注可乐定后,正常受试者、单侧臂丛神经损伤患者的受神经支配但非去神经支配的肢体以及四肢瘫痪者均出现手指皮肤血管舒张,表明这种反应是由于可乐定的中枢性抗交感神经作用。与正常受试者相比,四肢瘫痪者的血浆去甲肾上腺素水平低得多,输注可乐定后,仅正常受试者的血浆去甲肾上腺素水平大幅下降。血浆肾素活性未改变。对四肢瘫痪者进行膀胱刺激会导致血压升高和手指皮肤血管收缩。可乐定不能显著降低或消除四肢瘫痪者膀胱刺激后的升压和手指血管收缩反应,表明可乐定对脊髓节前神经元或外周突触前α2-肾上腺素能受体没有主要作用。
因此,可乐定是一种适用于分析不同循环系统疾病(如高血压和体位性低血压)中脊髓以上中枢控制水平的药物。